Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Primary prevention of defibrillator implantation after myocardial infarction: clinical practice and compliance to guidelines.

Sjöblom J, Ljung L, Frick M, Rosenqvist M, Frykman V.

Europace. 2012 Apr;14(4):490-5. doi: 10.1093/europace/eur354.

PMID:
22117032
2.

Are MADIT II criteria for implantable cardioverter defibrillator implantation appropriate for Chinese patients?

Siu CW, Pong V, Ho HH, Liu S, Lau CP, Li SW, Tse HF.

J Cardiovasc Electrophysiol. 2010 Mar;21(3):231-5. doi: 10.1111/j.1540-8167.2009.01609.x.

PMID:
19804551
4.

Improved survival associated with prophylactic implantable defibrillators in elderly patients with prior myocardial infarction and depressed ventricular function: a MADIT-II substudy.

Huang DT, Sesselberg HW, McNitt S, Noyes K, Andrews ML, Hall WJ, Dick A, Daubert JP, Zareba W, Moss AJ; MADIT-II Research Group..

J Cardiovasc Electrophysiol. 2007 Aug;18(8):833-8.

PMID:
17537209
5.

Structured care for patients after acute myocardial infarction: sudden cardiac death prevention--data from the Leiden MISSION! AMI study.

Atary JZ, Borleffs CJ, Liem SS, Bax JJ, van der Hoeven BL, Bootsma M, van der Wall EE, van Erven L, Schalij MJ.

Europace. 2010 Mar;12(3):378-84. doi: 10.1093/europace/eup420.

PMID:
20056593
6.

Implantable cardioverter defibrillator therapy for primary prevention of sudden cardiac death after myocardial infarction: implications of international guidelines.

Foley PW, Addison CE, Whinney SB, Patel K, Cunningham D, Frenneaux MP, Leyva F.

Pacing Clin Electrophysiol. 2009 Mar;32 Suppl 1:S131-4. doi: 10.1111/j.1540-8159.2008.02268.x.

PMID:
19250076
7.

Obesity as a risk factor for sustained ventricular tachyarrhythmias in MADIT II patients.

Pietrasik G, Goldenberg I, McNitt S, Moss AJ, Zareba W.

J Cardiovasc Electrophysiol. 2007 Feb;18(2):181-4.

PMID:
17338766
8.

Insufficient compliance with current implantable cardioverter defibrillator (ICD) therapy guidelines in post myocardial infarction patients is associated with increased mortality.

Pertzov B, Novack V, Zahger D, Katz A, Amit G.

Int J Cardiol. 2013 Jun 20;166(2):421-4. doi: 10.1016/j.ijcard.2011.10.132.

PMID:
22100182
9.

Ventricular tachycardia and sudden death after primary PCI-reperfusion therapy: impact on primary prevention of sudden cardiac death.

Paranskaya L, Akin I, Chatterjee T, Ritz A, Paranski P, Rehders T, Ince H, Schneider H, Nienaber CA, Bänsch D.

Herzschrittmacherther Elektrophysiol. 2011 Dec;22(4):243-8. doi: 10.1007/s00399-011-0160-z.

PMID:
22124800
10.

Outcomes of early risk stratification and targeted implantable cardioverter-defibrillator implantation after ST-elevation myocardial infarction treated with primary percutaneous coronary intervention.

Zaman S, Sivagangabalan G, Narayan A, Thiagalingam A, Ross DL, Kovoor P.

Circulation. 2009 Jul 21;120(3):194-200. doi: 10.1161/CIRCULATIONAHA.108.836791.

11.

Predictors of appropriate implantable cardioverter-defibrillator therapy during long-term follow-up of patients with coronary artery disease.

Blumer J, Wolber T, Hellermann J, Holzmeister J, Binggeli C, Duru F, Brunckhorst C.

Int Heart J. 2009 May;50(3):313-21.

12.

Relation of body mass index to sudden cardiac death and the benefit of implantable cardioverter-defibrillator in patients with left ventricular dysfunction after healing of myocardial infarction.

Choy B, Hansen E, Moss AJ, McNitt S, Zareba W, Goldenberg I; Multicenter Automatic Defibrillator Implantation Trial-II Investigators..

Am J Cardiol. 2010 Mar 1;105(5):581-6. doi: 10.1016/j.amjcard.2009.10.041.

PMID:
20185000
13.

ICD-implantation guidelines versus clinical practice: a prospective study of out-of-hospital cardiac arrest survivors.

Sterk B, van Alem AP, Tukkie R, Simmers TA, Koster RW.

Europace. 2004 May;6(3):179-83.

PMID:
15121066
14.

Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction.

Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, Fain E, Gent M, Connolly SJ; DINAMIT Investigators..

N Engl J Med. 2004 Dec 9;351(24):2481-8.

15.

Prognostic role of post-infarction C-reactive protein in patients undergoing implantation of cardioverter-defibrillators: design of the C-reactive protein Assessment after Myocardial Infarction to GUide Implantation of DEfibrillator (CAMI GUIDE) study.

Bellocci F, Biasucci LM, Gensini GF, Padeletti L, Raviele A, Santini M, Giubilato G, Landolina M, Biondi-Zoccai G, Raciti G, Sassara M, Castro A, Kheir A, Crea F.

J Cardiovasc Med (Hagerstown). 2007 Apr;8(4):293-9.

PMID:
17413310
16.

New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II.

Klein H, Auricchio A, Reek S, Geller C.

Am J Cardiol. 1999 Mar 11;83(5B):91D-97D. Review.

PMID:
10089848
17.

Clinical practice of defibrillator implantation after myocardial infarction: impact of implant time: results from the PreSCD II registry.

Völler H, Kamke W, Klein HU, Block M, Reibis R, Treusch S, Contzen K, Wegscheider K; PreSCD II registry investigators..

Europace. 2011 Apr;13(4):499-508. doi: 10.1093/europace/euq426.

18.

Long-term follow-up on high-rate cut-off programming for implantable cardioverter defibrillators in primary prevention patients with left ventricular systolic dysfunction.

Clementy N, Pierre B, Lallemand B, Marie O, Lemoine E, Cosnay P, Fauchier L, Babuty D.

Europace. 2012 Jul;14(7):968-74. doi: 10.1093/europace/eus028.

PMID:
22389416
Items per page

Supplemental Content

Support Center